A Drug That Erases an Immune Protein Entirely Enters Rheumatoid Arthritis Trials Without JAK Inhibitor Safety Warnings
The more mechanistically novel of Thursday's two programs is Evommune's. The company, which had staked its near-term story on EVO756 — an oral drug targeting a G-protein-coupled receptor — saw that bet dissolve over the spring and summer. EVO756 failed to meet its primary endpoint…